Lapatinib activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with trastuzumab, pertuzumab, and/or ado-trastuzumab emtansine (T-DM1).
Luis Baez-VallecilloAkshara S RaghavendraKenneth R HessCarlos H BarcenasStacy L MoulderDebu TripathyVicente ValeroRashmi K MurthyPublished in: Breast cancer research and treatment (2019)
L-based therapy is an active therapeutic option and remains a viable option for HER2 + MBC after prior trastuzumab, P and/or T-DM1.